SBIO - ALPS Medical Breakthroughs ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
35.95
+0.37 (+1.04%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close35.58
Open0.00
Bid35.94 x 900
Ask36.26 x 1100
Day's Range35.72 - 36.00
52 Week Range25.49 - 39.61
Volume57,110
Avg. Volume35,775
Net Assets185.28M
NAV35.58
PE Ratio (TTM)N/A
Yield2.22%
YTD Return27.40%
Beta (3Y Monthly)1.49
Expense Ratio (net)0.50%
Inception Date2014-12-30
Trade prices are not sourced from all markets
  • 7 Biotech ETFs That Should Remain Healthy
    InvestorPlace

    7 Biotech ETFs That Should Remain Healthy

    The healthcare sector is struggling this year. In 2018, the group was the best-performing sector in the S&P 500. This year, it's the worst. The Dow Jones U.S. Health Care Index is up just 10.20% year-to-date, but there are some pockets of strength and potential growth opportunities in the S&P 500's third-largest sector weight.Source: Shutterstock Biotechnology is one of those groups. Some biotech ETFs aren't setting the market ablaze this year, but broadly speaking, biotech ETFs are outperforming diversified healthcare funds. For example, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), the largest biotech ETF by assets, is up almost 10% year-to-date.The current market environment, marked by lower interest rates and escalating trade tensions, could actually favor biotech ETFs due to the groups' emphasis on the U.S. economy. Plus, the broader healthcare sector looks inexpensive relative to other defensive sectors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Health care, the worst-performing sector this year, trades at 15 times forward earnings, below the 17 times multiple on the S&P 500. By comparison, staples, utilities and REITs trade closer to 20 times earnings," reports CNBC. * 10 Generation Z Stocks to Buy Long Here are some biotech ETFs to consider right here, right now. SPDR S&P Biotech ETF (XBI)Expense ratio: 0.35% per year, or $35 on a $10,000 investment.The SPDR S&P Biotech ETF (NYSEARCA:XBI) is home to $4.15 billion in assets under management, making it one of the largest biotech ETFs, but XBI's size is not why it is being highlighted here. For active traders, XBI is worth a look right now because during the week starting Monday, Aug 5, half of XBI's 119 holdings report earnings, so there are plenty of catalysts that could move this fund in the near term.XBI is an equal weight ETF and as such tilts toward smaller biotech names as highlighted by an average market value of $10.6 billion for the fund's components, putting it in mid-cap territory. XBI status as an imminent earnings play is relevant because FactSet expects second-quarter earnings for the healthcare sector to rise an average of 2.1%, the second-best growth rate among the 11 S&P 500 sectors.What could be a challenge for XBI and other biotech ETFs over the near term is campaign-trail chatter about drug prices (many XBI components are considered pharmaceuticals makers), but in the fund's corner are decent valuations and status of many of its holdings as credible takeover targets. Invesco Dynamic Biotechnology & Genome ETF (PBE)Source: Shutterstock Expense ratio: 0.59%The Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is an ideal biotech ETF for investors looking for a smart beta approach to the space. PBE, which turned 14 years old in June, tracks the Dynamic Biotech & Genome Intellidex Index.That benchmark "is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value," according to Invesco. * 7 A-Rated Stocks Under $10 Smart beta is not always perfect, but its applications in the biotech ETF space are notable. Over the past three years, PBE has beaten a major cap-weighted index of biotechnology stocks by a margin of better than 3-to-1 with only slightly higher volatility. ALPS Medical Breakthroughs ETF (SBIO)Source: Shutterstock Expense ratio: 0.50% per yearThe ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) has long been a unique alternative to traditional biotech ETFs and with its emphasis on small-cap and smaller mid-cap stocks, SBIO can also be an alternative for risk-tolerant investors looking to replace standard small equity exposure.In addition to capping components' market values at the time of entry at $5 billion, SBIO's underlying index requires that those companies have at least one drug or therapy in Phase II or III Food and Drug Administration (FDA) trials. So while there can be no guarantees that SBIO holdings will become the next Amgen or Gilead, at least investors know the fund is not chock full of financially flimsy fly-by-night biotech stocks.And speaking of finances, SBIO components must have enough cash to survive at least two years to be included in the fund. That's a stiffer requirement than is found on standard small-cap ETFs, perhaps explaining why over the past three years SBIO is not just one of the best biotech ETFs, but one of the best small-cap funds, too. Global X Genomics & Biotechnology ETF (GNOM) Source: Shutterstock Expense ratio: 0.68%Having debuted in April, the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) is one of the newest biotech ETFs on the market. Rookie status aside, this Global X fund addresses a compelling, fast-growing corner of the healthcare market."There are several segments within the genomics field that stand to benefit from falling genetic testing costs, the rise of precision medicine ever-increasing amounts of genetic data, and other trends fueling genomics' disruption of health care," according to Global X research. * 10 High-Yield Monthly Dividend Stocks to Buy As an industry, genomics is not nearly as old some other healthcare groups, but the upside of that is that the industry offers plenty of growth potential via areas such as gene sequencing, gene editing, computational genomics and genetic diagnostics and more. Home to 40 stocks, a decent-sized lineup for a niche ETF like this, GNOM touches many of the exciting corners of the genomics investment thesis. ROBO Global Healthcare Technology and Innovation ETF (HTEC)Source: Shutterstock Expense ratio: 0.68%Having debuted in late June, the ROBO Global Healthcare Technology and Innovation ETF (NYSEARCA:HTEC) is the newest of biotech ETFs highlighted here and to be clear, it is not a dedicated biotech ETF. Rather, HTEC is designed as a play on the themes of healthcare disruption and innovation, but that can and should some biotechnology exposure. HTEC targets the ROBO Global Healthcare Technology and Innovation Index. "We anticipate that this technology revolution should profoundly transform the healthcare industry, offering a potential opportunity to investors over the next decade," according to ROBO Global. "It is about shifting the model from caring for the sick to one of prevention, prediction and eradication of diseases. It is about enhancing physicians' accuracy and therapies' efficacy. Finally, it is about lowering costs. The expected result: longer, healthier lifespans."HTEC has a broad lineup at 85 components, but a good percentage of those names dwell in the genomics and pharmaceuticals arenas, giving this fund some credibility as a biotech ETF. Importantly, the intersection of healthcare and artificial intelligence (AI), one of HTEC's points of emphasis, is real and growing."A.I. in health care could balloon to a $6.6 billion industry by 2021 form the $600 million back in 2014. A.I. funding has almost doubled to $2.3 billion in 2018, compared to $1.2 billion in 2017," according to ETF Trends. ARK Genomic Revolution Multi-Sector ETF (ARKG)Source: Shutterstock Expense ratio: 0.75%For those looking for active management with their genomics investments, an advisable strategy in many instances, the ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is one of the best funds to consider. "Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business," according to ARK Investment Management.ARKG usually holds 30 to 50 stocks, but the fund typically spans into a half dozen fast-growing corners of the biotech space, including CRISPIR, bioinformatics, molecular diagnostics and more. * 10 Small-Cap Stocks to Buy Before They Grow Up Past performance is never a guarantee of future returns, but the ARK team are excellent stock pickers. Over the past three years, ARKG is beating the largest biotech ETF by a margin of more than 8-to-1. Invesco S&P SmallCap Health Care ETF (PSCH)Source: Shutterstock Expense ratio: 0.29%The Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) is an almost biotech ETF. "Almost" because as its name implies, it's a diverse healthcare ETF, but when small-cap and healthcare stocks come together, biotechnology is usually involved.PSCH confirms as much as nearly 29% of its holdings, its largest industry weight, are biotechnology names. Earlier, I mentioned that healthcare stocks are trading at attractive valuations, but that's not the case with PSCH, which trades at 34x earnings. However, for investors that can stomach the added volatility, PSCH is worth the lofty multiples.Over the past three years, this biotech ETF was 320 basis points more volatile than the S&P SmallCap 600 Index, but the Invesco funds outperformed that index by nearly 2-to-1.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Generation Z Stocks to Buy Long * 5 Growth Stocks to Buy After the Rate Cut * 5 Dependable Dividend ETFs to Invest In The post 7 Biotech ETFs That Should Remain Healthy appeared first on InvestorPlace.

  • Why These Innovative Biotech ETFs Soaring
    Zacks

    Why These Innovative Biotech ETFs Soaring

    Strong M&A activity has sent shares of many small, innovative biotech companies surging

  • Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
    Zacks

    Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

    Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

  • ETF Trends

    Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal

    Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting ...

  • Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?
    Zacks

    Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?

    Though markets rallied probably on the undervalued status and a still-steady US economy, rising recessionary fears and full-scale trade war risks should brighten the appeal of safer ETFs.

  • ETF Trends

    3 Biotech Sector ETFs Bucked the Risk-Off Trend

    While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats to raise Chinese tariffs, biotechnology stocks and sector-related exchange traded ...

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • ETF Database

    A Targeted ETF to Capture M&A, Consolidation in the Biotech Space

    The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has typically tapped into these smaller innovators to fill out their own businesses. With increased merger and acquisition activity in the biotech sector, ETF investors may look to targeted plays to capture the up-and-coming companies.

  • ETF Trends

    Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook

    Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after FDA Commissioner Scott Gottlieb unexpectedly resigned, ...

  • Top ETF Stories of February
    Zacks

    Top ETF Stories of February

    Inside the top ETF events of the month of February.

  • InvestorPlace

    7 of the Best Biotech ETFs

    After slumping last year, biotechnology stocks and the related exchange traded funds (ETFs) are on the mend in 2019. Last year, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), the largest biotech ETF by assets, slipped 9.5%.With almost two months of 2019 in the books, IBB has recouped all of those losses and then some as the benchmark biotechnology ETF is higher by nearly 17% this year. Amid ongoing industry consolidation, attractive valuations for a group that is often richly valued and a strong broad market, catalysts are in place for more upside for biotechnology ETFs.Jefferies analyst Michael Yee "writes that third-party data shows that the fourth quarter saw not only the biggest actively managed fund outflows in the biopharma space in 15 years, but outflows that were double the biotech bear market of 2016," according to Barron's.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, flows data suggest investors need some convincing about returning to biotechnology ETFs. Year-to-date, IBB has lost $382.28 million in assets. * 7 IPOs to Get Excited for in 2019 Those outflows should convince investors to shy away from biotechnology ETFs. Here are some fine ideas among biotech ETFs to consider right here, right now. ALPS Medical Breakthroughs ETF (SBIO)Expense Ratio: 0.5% per year, or $50 on a $10,000 investment.For investors willing to take some more risk due to the fund's mid- and small-cap composition, the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) is one of the best alternatives to traditional biotech ETFs. SBIO member firms have market values ranging from $200 million to $5 billion.That puts the fund at the epicenter of some prominent biotech themes. SBIO is not designed to be a takeover fund, but with market caps that do not exceed $5 billion when the fund rebalances, SBIO components have frequently been mentioned as takeover targets or outright acquired in the fund's four-plus years on the market.Second, smaller biotech companies are often more sensitive to positive trial news than large-cap counterparts, which is relevant to SBIO because the fund only holds companies with drugs or treatments in Phase II of Phase III clinical trials. Invesco Dynamic Biotechnology & Genome ETF (PBE)Expense Ratio: 0.59%The Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is a biotech ETF to consider for investors looking for a unique weighting methodology. This $281.4 million fund follows the Dynamic Biotech & Genome Intellidex Index."The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value," according to Invesco. * 10 Blue-Chip Stocks to Lead the Market Over the past three years, this biotech ETF has handily outperformed IBB, and much of that out-performance is attributable to the size factor. Currently, over 70% of PBE's 29 holdings are classified as mid- or small-cap stocks. Invesco S&P SmallCap Health Care ETF (PSCH)Expense Ratio: 0.29%Small-cap ETFs can offer big returns, and for investors willing to get tactical, some sector funds in this space can really pack a punch. That group certainly includes the Invesco S&P SmallCap Health Care ETF(NASDAQ:PSCH).As its name implies, PSCH is a broader healthcare fund, not a dedicated biotech ETF, but the combination of healthcare and small-cap stocks often means significant biotechnology exposure. PSCH obliges with a 19.46% to biotechnology stocks. Not surprisingly, PSCH is predominantly a small-cap growth fund as about 72% of its 69 holdings are classified as small-cap growth stocks.Since inception nearly nine years ago, PSCH has beaten the S&P SmallCap 600 Index by more than 700 basis points. Global X Longevity Thematic ETF (LNGR)Expense Ratio: 0.5%The Global X Longevity Thematic ETF (NASDAQ:LNGR) is a thematic fund focusing on the issue of rapidly aging populations in some of the world's largest economies. Via that focus, LNGR has some credibility as a biotechnology ETF as biotech stocks represent around a third of the fund's weight.While LNGR is a highly focused fund and still small in terms of assets, there are compelling long-term trends backing its investment thesis. * 7 Cheap Stocks That Make the Grade "As more people age, there will simply be greater demand for treatments, both old and new, to prevent, mitigate and ideally cure such diseases," according to Global X research. "Innovations in technology and biotech research, including the use of genomic data and bioinformatics for personalized care, can offer further solutions in this space." ARK Genomic Revolution ETF (ARKG)Expense Ratio: 0.75%The actively managed ARK Genomic Revolution ETF (NYSEARCA:ARKG) is not a biotechnology ETF, but it focuses on some of the most compelling healthcare opportunities, including bioinformatics, CRISPR, molecular diagnostics, stem cell therapies and more."Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business," according to ARK Investment Management.The $254 million ARKG usually holds 30 to 50 stocks and the current weighted average market value of its holdings is $30 billion. While ARKG is pricier than traditional healthcare and biotech ETFs, the fund is worth the higher fee. Over the past three years, ARKG is up 91.3%, nearly doubling the returns of the S&P 500 Health Care Index. First Trust NYSE Arca Biotechnology Index Fund (FBT)ExpenseRatio: 0.56%The First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) is one of the largest and more traditional biotech ETFs. Home to 30 stocks, FBT follows the NYSE Arca Biotechnology Index.Although FBT appears to be a basic big pharma ETF, none of its holdings exceed weights of 3.94% and the size factor is at play with this fund as highlighted by a median market capitalization of $8.18 billion for its holdings. * 9 High-Growth Stocks to Buy Now for Monster Returns Tilting toward small biotech stocks has helped FBT top the largest cap-weighted biotech ETF by a margin of better than 2-to-1 over the past 36 months. During that span, FBT has only been slightly more volatile than its cap-weighted rival. Principal Healthcare Innovators Index ETF (BTEC)Expense Ratio: 0.42%The Principal Healthcare Innovators Index ETF (NASDAQ:BTEC), which debuted in August 2016, is another example of a thematic approach to healthcare investing. BTEC tracks the Nasdaq U.S. Healthcare Innovators Index, which is comprised of early stage, small-cap names."These are primarily biotechnology and life science, which have the potential to create cures for cancer, develop new medical technologies, or spearhead other medical advances," according to ETF Trends.BTEC is not a pure biotech ETF, but at the end of last year, 60.57% of the fund's weight was allocated to biotech stocks. When BTEC rebalances none of its holdings exceed weights of 3% and at the end of 2018, the fund's top 10 holdings represented just over 29% of its weight. Those are two traits that help diminish concentration risk.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post 7 of the Best Biotech ETFs appeared first on InvestorPlace.

  • Biotech ETFs Jump on Roche-Spark Deal
    Zacks

    Biotech ETFs Jump on Roche-Spark Deal

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

  • ETF Trends

    Spark Therapeutics Acquisition Sparks Rally in Biotechnology ETFs

    Biotechnology stocks and sector-specific ETFs climbed Monday after Roche (RHHBY) acquired gene therapy researcher Spark Therapeutics (ONCE). Among the best performing ETFs of Monday, the Invesco Dynamic ...

  • InvestorPlace

    5 of the Best Thematic ETFs to Consider

    There really is an exchange-traded fund (ETF) for that, whatever "that" is. Or at least there is a very good chance there is an ETF for what was previously an obscure or hard-to-access market segment.These products were once called niche ETFs. Today, thematic ETF is the more politically correct and more appropriate vernacular. Whatever terminology investors choose, there is no denying this universe of funds is growing. Some official lists say there are dozens of thematic ETFs in the U.S., but a case can be made there are hundreds -- and the universe is growing."Thematic investing follows certain social, economic, corporate, demographic, or other themes that are popular in society," according to Fidelity. "The opportunity comes when more people believe in the same themes and investment is driven in the direction of these companies. The shift of capital ultimately could drive superior performance in a thematic portfolio if the companies in the indexes benefit from the business."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThere several traits that the best ETFs of this type share, including first-mover advantage; providing access to compelling, fast-growing niches; and impressive performances. Some thematic ETFs fight a battle to attract enough assets to lure other investors, an often vicious circle, but new data indicate more advisors and investors are willing to nibble at new, small funds. That could pave the way for increased adoption of thematic ETFs. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? Here are some of the best ETFs to consider. Best ETFs: ETFMG Alternative Harvest ETF (MJ)Expense Ratio: 0.75% per year, or $75 on a $10,000 investment.The ETFMG Alternative Harvest ETF (NYSEARCA:MJ) is a prime example of a successful thematic ETF as this fund recently topped $1 billion in assets under management. MJ checks several of the aforementioned boxes, notably first-mover advantage and exposure to a fast-growing theme. In fact, the MJ ETF still has the market for U.S.-listed cannabis ETFs to itself.Of course, there is performance. Sometimes. Year-to-date, MJ is up 38%, but that is after the fund lost almost 22% last year. For ETF investors, MJ is the clear choice for accessing the cannabis boom, which is being facilitated by relaxed regulations at the state level. Marijuana is legal for adult recreational use in several states and more states are considering moves to legalize cannabis for medicinal and/or recreational purposes.Some cash-strapped states see the money states such as California and Colorado are raking in and could look to relax marijuana laws to bolster state coffers. That bodes well for MJ over the long-term. Pacer Benchmark Industrial Real Estate SCTR ETF (INDS)Expense Ratio: 0.6%Some of the best ETFs provide access to the real estate sector and do so in unique fashion. The Pacer Benchmark Industrial Real Estate SCTR ETF (NYSEARCA:INDS) hails from a family of unique, thematic ETFs with real estate exposure. INDS offers exposure to one of the real estate industry's most compelling growth segments.Industrial real estate investment trusts (REITs), including those residing in INDS, own facilities and warehouses used to store goods for the e-commerce boom. Industrial REITs are "important because investing in this space is a roundabout way to play the e-commerce sector without exposure to volatile and expensive retail equities like Amazon, Walmart and more," according to Pacer. * 9 U.S. Stocks That Are Coming to Life Again INDS is beating the largest U.S. REIT ETF by nearly 360 basis points this years and this thematic ETF, which will be one year old in May, does not skimp on yield, as highlighted by a 30-day SEC yield of 3%. Global X Internet of Things ETF (SNSR)Expense Ratio: 0.68%The Internet of Things (IoT) is at the epicenter of scores of everyday functions. Those include development and manufacturing of semiconductors and sensors, integrated products and solutions, and applications serving smart grids, smart homes, connected cars, and the industrial internet, according to Global X.The Global X Internet of Things ETF (NASDAQ:SNSR) is the first ETF to provide dedicated IoT access. This thematic ETF tracks the Indxx Global Internet of Things Thematic Index and holds 50 stocks, most of which are technology names, but there is some healthcare exposure as well.Bolstering the case for SNSR is IoT's myriad consumer and industrial applications. The latter includes cloud computing, robotics and more."In addition to the development of smart transportation systems to support autonomous vehicles, the IoT is expected to improve energy grid efficiency, utilities services, commercial and residential property management, and the overall growth of smart cities," according to Global X research. "The global smart grid market is forecasted to reach $61.3 billion by 2023, up from $23.8 billion in 2018, with a compound annual growth rate (CAGR) of 20.9%." ALPS Disruptive Technologies ETF (DTEC)Expense Ratio: 0.5%Why access just one interesting theme when you can get 10 in one ETF? The ALPS Disruptive Technologies ETF (NYSEARCA:DTEC) does just that, making this thematic fund one of the best ETFs for multi-theme exposure.DTEC equally weights 10 disruptive technological themes, including cloud computing, fintech, healthcare innovation, IoT and mobile payments. This thematic ETF equally weights it components as well, which helps reduce concentration risk while giving investors some benefit of the size factor. * Buy These 5 Stocks to Play the Megatrend of the Century DTEC's strategy is working. This year and over the past year, this thematic ETF is topping the Nasdaq-100 Index by impressive margins. It's also beating the Russell 1000 Growth Index over those periods as well, making it one of the best ETFs for tech investing. ALPS Medical Breakthroughs ETF (SBIO)Expense Ratio: 0.5%Although the healthcare sector is often thought of as a defensive destination, there are plenty of exciting thematic ETFs tracking this space. The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) is definitely one of those funds.Traditional biotech ETFs focus on large-cap stocks, but SBIO is anything but traditional."Stocks included in the Underlying Index must also sustain an average daily trading volume in excess of $1 million for the 90-day period preceding an Underlying Index reconstitution. Constituents must be able to sustain the monthly rates at which they use shareholder capital ('cash burn rates') for at least 24 months," according to ALPS.SBIO is one of the best ETFs to capitalize on its strategy. Over the past three years, this thematic ETF has beaten the Nasdaq Biotechnology Index by a better than 2-to-1 margin.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post 5 of the Best Thematic ETFs to Consider appeared first on InvestorPlace.

  • The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK
    Zacks

    The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK

    The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK

  • Small Caps Taking Charge of the Bulls: 6 ETF Winners YTD
    Zacks

    Small Caps Taking Charge of the Bulls: 6 ETF Winners YTD

    we have presented six top performing small-cap ETFs of the current rally that have gained in double digits and will continue their outperformance.

  • Top ETFs of Last Week
    Zacks

    Top ETFs of Last Week

    These ETFs have had a strong last week.

  • ETF Trends

    Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

    Biotechnology stocks and sector-related ETFs were among the best performers Monday after Eli Lilly (NYSE: LLY) said it will acquire Loxo Oncology Inc. (NasdaqGS: LOXO) for $8 billion. Among the best performers ...

  • 6 Wining ETF Areas From a Late Santa Rally
    Zacks

    6 Wining ETF Areas From a Late Santa Rally

    These sector ETFs have made the most of the start of this Santa Rally.

  • Investopedia

    An ETF That Aims to Capitalize on Upcoming Drug Breakthroughs

    In the biotechnology and pharmaceuticals industries, pride of place can be a crucial factor in a company's success. Companies race to develop products and new drugs in the hopes that they will advance through multiple phases of testing by the U.S. Food and Drug Administration (FDA). Although it's rare for a new drug to officially receive approval, when this happens, it is a tremendous boon for the developing company.

  • 10 Best ETFs for 2018: Still a Close Race at the Head of the Pack
    InvestorPlace

    10 Best ETFs for 2018: Still a Close Race at the Head of the Pack

    Welcome to the final quarter of the 2018 Best ETFs contest, which is, admittedly, also our first Best ETFs contest.

  • InvestorPlace

    Best ETFs for 2018: Don’t Sweat This Quarter for the SBIO ETF

    Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO), my choice for the InvestorPlace Best ETFs for 2018 competition, is enduring its worst quarter of 2018. With just a few trading days left in the third quarter, SBIO is sporting a quarter-to-date loss of 0.2%.

  • 10 ETFs to Buy for a Rally
    InvestorPlace

    10 ETFs to Buy for a Rally

    As of Sept. 5, the S&P 500 is up 8.3% year-to-date. The tech-heavy Nasdaq-100 Index is up more than double that, sporting a 2018 gain of 17.8%.